Gaining efficacy results in just 3 months will increase the likelihood your patient remains compliant with therapy—which will increase her chances of avoiding a dreaded fracture.
With a menu of highly specific bone marker assays—such as the Elecsys β-CrossLaps—that determine how well her osteoporosis medications are working, there’s no longer a need to wait 2 years for your patient’s next DXA scan.
References:
1. Facts about Bone Health. National Osteoporosis Foundation Web site. https://www.bonehealthpolicyinstitute.org/bone-facts Accessed April 21, 2021.
2. What is osteoporosis? National Osteoporosis Foundation Web site. https://nof.org/articles/7. Accessed November 20, 2018.
3. Warriner AH, Curtis JR. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol. 2009;21(4):356-362.
4. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006;119(4A):25S-31S.
*Due to osteoporosis; in women over age 50.
